Advertisement

Focus On Breast Cancer

Managing a Long and Winding Road: Estrogen Receptor–Positive Breast Cancer

We review key topics in the management of estrogen receptor (ER)–positive human epidermal growth factor receptor 2–negative breast cancer. The single biggest challenge in management of this disease is late relapse, and we review new methods for identifying which patients are at risk of late relapse and potential therapeutic approaches in clinical trials.

Podcast: SONIA, NATALEE, and Other Advances in Breast Cancer at ASCO23

Podcast: SONIA, NATALEE, and Other Advances in Breast Cancer at ASCO23

Drs. Allison Zibelli and Arielle Heeke discuss the NATALEE trial’s novel approach to high-risk HR+ breast cancer, the potential of delaying CDK4/6 inhibitors in HR+, HER2-negative mBC to decrease toxicities and costs in the SONIA trial, and de-escalation strategies in HER2+ early-stage breast cancer.

Managing a Long and Winding Road: Estrogen Receptor–Positive Breast Cancer

Managing a Long and Winding Road: Estrogen Receptor–Positive Breast Cancer

We review key topics in the management of estrogen receptor (ER)–positive human epidermal growth factor receptor 2–negative breast cancer. The single biggest challenge in management of this disease is late relapse, and we review new methods for identifying which patients are at risk of late relapse and potential therapeutic approaches in clinical trials.

Role of Immunotherapy in Breast Cancer

Role of Immunotherapy in Breast Cancer

The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust data to date for ICI exist for triple-negative breast cancer (TNBC).

Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

Approximately 70% of newly diagnosed breast cancers are early-stage, estrogen receptor–positive (ER-positive) and human epidermal growth factor receptor 2–negative (HER2-negative). With optimal adjuvant systemic therapy, including 5-10 years of adjuvant endocrine therapy (ET) with either tamoxifen or an aromatase inhibitor, most patients will be cured, and mortality from breast cancer has declined by over one-third in the past 3 decades.

Treatment of Breast Cancer in Young Adults

Treatment of Breast Cancer in Young Adults

Although breast cancer is rare and understudied in adults age 40 and younger, recent epidemiologic data show an increasing incidence of breast cancer among young women in the United States and ongoing inferior long-term outcomes.

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Recept

Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Recept

The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer. In this analysis, we evaluated palbociclib exposure and discontinuation in PALLAS.